A new method for in vivo measurement of brain monoamine oxidase activity

O. Inoue,Toshiyoshi Tominaga,T. Yamasaki,H. Kinemuchi

DOI: https://doi.org/10.1016/S0278-5846(84)80026-3

IF: 5.201

1984-12-31

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Abstract:

What problem does this paper attempt to address?

39P CSF-1R Inhibitor (C019199) Enhances Antitumor Effect in Combination with Anti-Pd-1 Therapy on Murine Breast Cancer Models

J. Zheng,X. Luo,F. Ye,X. Lin,L. Xia,J. Wu,J. Lian

DOI: https://doi.org/10.1016/j.annonc.2020.10.059

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:Colony-stimulating factor-1 (CSF-1) is the primary regulator of mononuclear phagocytic cells. CSF-1 plays an important role in recruiting macrophages to tumor environment. Overexpression of CSF-1 and its ligand, colony-stimulating factor-1 receptor (CSF-1R), have been reported to be associated with the development of various types of cancers, such as breast, ovarian, and colorectal cancer. This study aims to investigate the treatment effects of a new CSF-1R inhibitor named C019199 in murine breast cancer (BC) models when administered alone or in combination with anti-PD-1 antibody. Inhibition of CSF-1R was investigated in the murine bone marrow derived macrophages (BMDMs) for cell-based assay. Furthermore, the immunocompetent Balb/c mice were subcutaneously implanted 4T1 breast cancer cells in the right flank. Mice were randomized into groups of 9 and treated with C019199 (orally, 30 mg, 60mg or 120 mg/kg/d), either alone or in combination with anti-mouse PD-1 antibody (intraperitoneally, 10 mg/kg). 1 of 9 groups was treated with single-agent Docetaxel (intraperitoneally, 10 mg/kg). The animal body weight and tumor growth were monitored twice a week. Results were analyzed by 2-way ANOVA with Bonferroni's test. 1. C019199 inhibited the murine colony-stimulating factor-1 receptor (CSF-1R) with an IC50 of about 8.0nM in cell-based assay. 2. C019199 inhibited tumor growth in murine BC models. The combination of C019199 and anti-PD-1 had better synergistic antitumor efficacy than single-agent. Balb/c mice implanted 4T1 cells were treated with C019199 alone or combined with anti-PD1 for 14 days. The antitumor efficacy and treatment detail (Table) were detected.Table: 39PEffect of C019199 on body weight and tumor size in murine 4T1 breast cancer modelsGroupAdministration regimenTumor size (mm3,Mean±SEM)Rate% of average body weight changeDay 0Day 14VehicleQD x 1467.11 ± 3.011705.69 ± 130.9613.76%Anti-mPD-1Day 0, 3, 7, 1066.82 ± 3.051343.55 ± 118.6516.43%DocetaxelDay 0, 766.88 ± 3.111023.00 ± 68.19****4.21%C019199QD x 1467.07 ± 3.171074.32 ± 59.31****11.01%C019199QD x 1466.76 ± 3.05927.24 ± 65.68****7.97%C019199QD x 1466.69 ± 2.99671.71 ± 62.56****2.18%Anti-mPD-1Day 0, 3, 7, 1066.62 ± 2.941079.65 ± 64.05****13.25%C019199QD x 14Anti-mPD-1Day 0, 3, 7, 1066.53 ± 2.86794.21 ± 105.82****10.50%C019199QD x 14Anti-mPD-1Day 0, 3, 7, 1066.41 ± 2.72619.62 ± 25.10****4.85%C019199QD x 14*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared with vehicle group. SEM, standard error of mean. Open table in a new tab *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared with vehicle group. SEM, standard error of mean. C019199 is a new tyrosine kinase inhibitor of CSF-1R. Single-agent C019199 showed dose-dependently inhibition in murine 4T1 BC tumors. C019199 combined with anti-PD-1 had better antitumor efficacy than C019199 alone. Assessed by animal body weight, such combination therapy was well tolerated. The mechanisms of C019199-mediated immunomodulatory effects in combination with anti-PD-1 need further exploration.
Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

Zhang Ying,Liu Qiuzi,Wei,Zhang Guoan,Yan Siyuan,Dai Rongrong,Sun Ying,Su Dubo,Lv Shun,Xia Yong,Li Jing,Li Changlin

DOI: https://doi.org/10.1186/s12885-021-08841-1

IF: 4.638

2021-01-01

BMC Cancer

Abstract:Background Bortezomib (BZM), alone or in combination with other chemotherapies, has displayed strong anticancer effects in several cancers. The efficacy of the combination of BZM and mitoxantrone (MTX) in treating prostate cancer remains unknown. Methods Anticancer effects of combination of BZM and MTX were determined by apoptosis and proliferation assay in vivo and in vitro. Expression of β-Catenin and its target genes were characterized by western blot and Real-time PCR. Results BZM significantly enhanced MTX-induced antiproliferation in vivo and in vitro. Mice administered a combination of BZM and MTX displayed attenuated tumor growth and prolonged survival. BZM significantly attenuated MTX-induced apoptosis. Moreover, the combination of BZM and MTX contributed to inhibition of the Wnt/β-Catenin signaling pathway compared to monotherapy. Conclusions This study demonstrates that BZM enhances MTX-induced anti-tumor effects by inhibiting the Wnt/β-Catenin signaling pathway in prostate cancer cells.
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer

Leticia Tordesillas,Maria Cecilia Ramello,Tao Li,Chen Hao Lo,Janis de la Iglesia,Emiliano Roselli,Ismahène Benzaïd,Xuefeng Wang,Youngchul Kim,Daniel Abate-Daga,Jeremy S. Frieling,Xiomar E. Bustos,Ryan T. Bishop,Junior E. Cianne,Sebastian A. Snedal,Conor C. Lynch

DOI: https://doi.org/10.1126/sciadv.adf0108

IF: 13.6

2023-05-05

Science Advances

Abstract:Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine model of bone mCRPC, γδ CAR-T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of established tumors, combined with increased survival and reduced cancer-associated bone disease. Pretreatment with ZOL, a U.S. Food and Drug Administration–approved bisphosphonate prescribed to mitigate pathological fracture in mCRPC patients, resulted in CAR-independent activation of γδ CAR-T cells, increased cytokine secretion, and enhanced antitumor efficacy. These data show that the activity of the endogenous Vγ9Vδ2 T cell receptor is preserved in CAR-T cells, allowing for dual-receptor recognition of tumor cells. Collectively, our findings support the use of γδ CAR-T cell therapy for mCRPC treatment.

multidisciplinary sciences
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny,Valerya Semenisty,Teresa Macarulla,Erkut Borazanci,Brian M. Wolpin,Salomon M. Stemmer,Talia Golan,Ravit Geva,Mitesh J. Borad,Katrina S. Pedersen,Joon Oh Park,Robert A. Ramirez,David G. Abad,Jaime Feliu,Andres Muñoz,Mariano Ponz-Sarvise,Amnon Peled,Tzipora M. Lustig,Osnat Bohana-Kashtan,Stephen M. Shaw,Ella Sorani,Marya Chaney,Shaul Kadosh,Abi Vainstein Haras,Daniel D. Von Hoff,Manuel Hidalgo

DOI: https://doi.org/10.1038/s41591-020-0880-x

IF: 82.9

2020-05-25

Nature Medicine

Abstract:Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative pathways. CXC chemokine receptor 4 (CXCR4) blockade promotes T cell tumor infiltration and is synergistic with anti-PD-1 therapy in PDAC mouse models. We conducted a phase IIa, open-label, two-cohort study to assess the safety, efficacy and immunobiological effects of the CXCR4 antagonist BL-8040 (motixafortide) with pembrolizumab and chemotherapy in metastatic PDAC (<a href="https://clinicaltrials.gov/ct2/show/NCT02826486?term=NCT02826486">NCT02826486</a>). The primary outcome was objective response rate (ORR). Secondary outcomes were overall survival (OS), disease control rate (DCR) and safety. In cohort 1, 37 patients with chemotherapy-resistant disease received BL-8040 and pembrolizumab. The DCR was 34.5% in the evaluable population (modified intention to treat, mITT; <i>N</i> = 29), including nine patients (31%) with stable disease and one patient (3.4%) with partial response. Median OS (mOS) was 3.3 months in the ITT population. Notably, in patients receiving study drugs as second-line therapy, the mOS was 7.5 months. BL-8040 increased CD8<sup>+</sup> effector T cell tumor infiltration, decreased myeloid-derived suppressor cells (MDSCs) and further decreased circulating regulatory T cells. In cohort 2, 22 patients received BL-8040 and pembrolizumab with chemotherapy, with an ORR, DCR and median duration of response of 32%, 77% and 7.8 months, respectively. These data suggest that combined CXCR4 and PD-1 blockade may expand the benefit of chemotherapy in PDAC and warrants confirmation in subsequent randomized trials.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Jeetendra Eswaraka,Anand Giddabasappa,Guangzhou Han,Kush Lalwani,Koleen Eisele,Zheng Feng,Timothy Affolter,James Christensen,Gang Li,Jeetendra Eswaraka,Anand Giddabasappa,Guangzhou Han,Kush Lalwani,Koleen Eisele,Zheng Feng,Timothy Affolter,James Christensen,Gang Li

DOI: https://doi.org/10.1186/1471-2407-14-742

IF: 4.638

2014-10-02

BMC Cancer

Abstract:BackgroundCastration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (VEGFR2 and c-MET inhibitor), was shown to have efficacy on bone lesions in patients. In this study we tested multi-kinase inhibitors: axitinib (VEGFR inhibitor) and crizotinib (c-MET inhibitor) in a combination trial in mice models.MethodsVCaP-Luc cells were grown as subcutaneous implants in intact and castrated NOD-SCID-gamma (NSG) mice to confirm the androgen dependency. For bone metastasis model two cohorts of NSG mice (castrated and intact) received orthotopic injection of VCaP-Luc cells into the bone marrow cavity of left tibia. Mice were monitored weekly for tumor growth using bioluminescence imaging. Animals were randomized into 4 groups based on the tumor bioluminescence signal: vehicle, crizotinib alone, axitinib alone, crizotinib and axitinib in combination. Animals were imaged weekly by in vivo 2-D X-ray imaging to monitor bone remodeling. At the end of the study animals were euthanized and both tibias were extracted for ex vivo high-resolution 3-D micro-computed tomography (μCT) imaging.ResultsSubcutaneous model showed that androgen stimulation may be helpful but not essential for the growth of VCaP-Luc cells. VCaP-Luc cells grown intra-tibially in intact animals caused extensive remodeling of bone with mixed osteoblastic (bone formation) and osteolytic (bone matrix dissolution) lesions. The osteoblastic lesions were predominant and at times extended beyond the tibial shaft into the surrounding tissue. In contrast, only osteolytic lesions were prominent throughout the study in castrated animals. Treatment with crizotinib alone reduced the osteolytic lesions in castrated animals. Axitinib alone reduced the osteoblastic lesions in the intact animals. Combination therapy with axitinib and crizotinib remarkably inhibited the tibial remodeling by VCaP-Luc cells which resulted in a significant reduction of both osteoblastic and osteolytic lesions.ConclusionOur data show that combined inhibition of c-MET and VEGFR can be beneficial for treatment of metastatic bone disease in CRPC and that the drugs act on two different stages of the disease.

oncology
Generating Broadcast Programs that Support Range Queries

K. Tan,J. Yu

DOI: https://doi.org/10.1109/69.706064

IF: 9.235

1998-07-01

IEEE Transactions on Knowledge and Data Engineering

Abstract:To disseminate information via broadcasting, a data server must construct a broadcast "program" that meets the needs of the client population. Existing works on generating broadcast programs have shown the effectiveness of nonuniform broadcast programs in reducing the average access times of objects for nonuniform access patterns. However, these broadcast programs perform poorly for range queries. The article presents a novel algorithm to generate broadcast programs that facilitate range queries without sacrificing much on the performance of single object retrievals.
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Sumit K Subudhi,Bilal A Siddiqui,Ana M Aparicio,Shalini S Yadav,Sreyashi Basu,Hong Chen,Sonali Jindal,Rebecca S S Tidwell,Ashwin Varma,Christopher J Logothetis,James P Allison,Paul G Corn,Padmanee Sharma

DOI: https://doi.org/10.1136/jitc-2021-002919

IF: 12.469

2021-10-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Immune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) promotes intratumoral T cell infiltration but induces upregulation of PD-1 and programmed death ligand-1 (PD-L1) within the prostate TME. Combined anti-CTLA-4 plus anti-PD-1 can partly overcome this adaptive resistance and was recently shown to augment responses in patients with mCRPC with measurable disease. Although bone is the most common site of metastasis in prostate cancer, patients with bone-predominant disease are frequently excluded from trials because they lack measurable disease, which limits assessment of disease progression and tissue sampling. We therefore designed this study to investigate combined ICT in mCRPC to bone. Hypothesis Combined anti-CTLA-4 (tremelimumab) plus anti-PD-L1 (durvalumab) is safe and well tolerated in patients with chemotherapy-naïve mCRPC to bone. Patients and methods In this single-arm pilot study, men with chemotherapy-naïve mCRPC to bone received tremelimumab (75 mg intravenous) plus durvalumab (1500 mg intravenous) every 4 weeks (up to four doses), followed by durvalumab (1500 mg intravenous) maintenance every 4 weeks (up to nine doses). The primary endpoint was incidence of adverse events. Secondary endpoints included serum prostate-specific antigen (PSA), progression-free survival (PFS), radiographic PFS (rPFS), and maximal PSA decline. Results Twenty-six patients were treated between August 8, 2017 and March 28, 2019. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 11 patients (42%), with no grade 4 or 5 events. TRAEs leading to discontinuation occurred in three patients (12%). PSA decline ≥50% occurred in three patients (12%). Six patients (24%) achieved stable disease for >6 months. At a median follow-up of 43.6 months, median rPFS was 3.7 months (95% CI: 1.9 to 5.7), and median overall survival was 28.1 months (95% CI: 14.5 to 37.3). Post-treatment evaluation of the bone microenvironment revealed transcriptional upregulation in myeloid and neutrophil immune subset signatures and increased expression of inhibitory immune checkpoints. Conclusions Tremelimumab plus durvalumab was safe and well tolerated in patients with chemotherapy-naïve mCRPC to bone, with potential activity in a small number of patients as measured by rPFS. Combination of CTLA-4 and PD-L1 blockade with therapies targeting the myeloid compartment or other inhibitory immune receptors may be necessary to overcome mechanisms of resistance within prostate bone microenvironment. Trial registration number NCT03204812 .

oncology,immunology
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models

C. Festuccia,E. Di Cesare,S. Pompili,E. Jannini,L. Ventura,E. Ricevuto,P. Muzi,A. Mancini,C. Mattei,G. Gravina,L. Biordi

DOI: https://doi.org/10.1002/pros.23007

2015-07-01

The Prostate

Abstract:The majority of prostate cancer (Pca) patient morbidity can be attributed to bone metastatic events, which poses a significant clinical obstacle. Therefore, a better understanding of this phenomenon is imperative and might help to develop novel therapeutic strategies. Stromal cell‐derived factor 1α (SDF‐1α) and its receptor CXCR4 have been implicated as regulators of bone resorption and bone metastatic development, suggesting that agents able to suppress this signaling pathway may be used as pharmacological treatments. In this study we studied if two CXCR4 receptor antagonists, Plerixafor and CTE9908, may affect bone metastatic disease induced by Pca in preclinical experimental models

Biology,Medicine
[Clinical Efficacy of Docetaxel Combined with Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer].

G C Bai,Y Song,J Jin,W Yu,Z S He

DOI: https://doi.org/10.19723/j.issn.1671-167x.2021.04.011

2021-01-01

Abstract:OBJECTIVE:To observe the early efficacy and toxicity of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS:From May 2017 to July 2019, fifteen patients with mCRPC treated in Peking University First Hospital were collected. The median age was 70 years (43-77 years), and the pathological types were all adenocarcinoma, which was confirmed as distant metastasis by imaging examination. They were given the chemotherapy of docetaxel combined with carboplatin. The specific method was as follows: each cycle was 28 days. Androgen deprivation therapy was administered routinely throughout the treatment period. Blood routine, liver and kidney function, blood clotting function and prostate-specific antigen (PSA) tests were performed before each cycle. Docetaxel was administered intravenously on the first day of each cycle at a dose of 75 mg/m2, and carboplatin was administered intravenously on the second day at the dose calculated by Calvert formula. The main outcome measures including PSA decline range, pain remission rate and occurrence of adverse reactions were observed and analyzed. RESULTS:Among the 15 patients, 12 had completed at least 4 cycles of chemotherapy and had short-term efficacy evaluation. PSA decline range > 50% was observed in 8 patients (66.7%). Among the 9 patients with bone pain, remarkable pain relief was observed in 4 patients (44.4%). Among the 4 patients with measurable metastatic lesions, 2 achieved partial response, 1 was evaluated as stable disease, and 1 was evaluated as progressive disease. The main adverse reactions of chemotherapy included bone marrow suppression, gastrointestinal reactions, fatigue and neurological disorders, and most of them were within the tolerable range. CONCLUSION:This report is a case series study of docetaxel combined with carboplatin in the treatment of mCRPC reported in China and the conclusions are representative. The chemotherapy of docetaxel combined with carboplatin has positive short-term efficacy and high safety in patients with mCRPC, which is worthy of further promotion and exploration in clinical practice.
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models

Nisha Gupta,Hiroki Ochiai,Yoshinori Hoshino,Sebastian Klein,Jozef Zustin,Rakesh R. Ramjiawan,Shuji Kitahara,Nir Maimon,Despina Bazou,Sarah Chiang,Sen Li,Daniel H. Schanne,Rakesh. K. Jain,Lance L. Munn,Peigen Huang,Sergey V. Kozin,Dan G. Duda

DOI: https://doi.org/10.3390/cancers15041021

2023-02-06

Cancers

Abstract:Radiotherapy (RT) is a standard treatment for patients with advanced prostate cancer (PCa). Previous preclinical studies showed that SDF1α/CXCR4 axis could mediate PCa metastasis (most often to the bones) and cancer resistance to RT. We found high levels of expression for both SDF1α and its receptor CXCR4 in primary and metastatic PCa tissue samples. In vitro analyses using PCa cells revealed an important role of CXCR4 in cell invasion but not radiotolerance. Pharmacologic inhibition of CXCR4 using AMD3100 showed no efficacy in orthotopic primary and bone metastatic PCa models. However, when combined with RT, AMD3100 potentiated the effect of local single-dose RT (12 Gy) in both models. Moreover, CXCR4 inhibition also reduced lymph node metastasis from primary PCa. Notably, CXCR4 inhibition promoted the normalization of bone metastatic PCa vasculature and reduced tissue hypoxia. In conclusion, the SDF1α/CXCR4 axis is a potential therapeutic target in metastatic PCa patients treated with RT.

oncology
Improvement of Docetaxel Efficacy through Simultaneous Blockade of Transcription Factors NF-κB and STAT-3 Using Pentoxifylline and Stattic in Prostate Cancer Cells

José Roberto Cruz-Lozano,Georgina Hernández-Flores,Pablo Cesar Ortiz-Lazareno,Luis Arturo Palafox-Mariscal,Katia Carolina Vázquez-Ibarra,Karen Lilith González-Martínez,María Martha Villaseñor-García,Alejandro Bravo-Cuellar

DOI: https://doi.org/10.3390/cimb46090605

2024-09-14

Abstract:Prostate cancer (PCa) is a common and deadly disease in men. It is often diagnosed at advanced stages, at which point patients are treated mainly with docetaxel (DTX), which is effective but limited by resistance and side effects. Overactivation of the transcription factors NF-κB and STAT-3 plays a critical role in the development, progression, and chemoresistance of PCa. In this regard, the blockade of NF-κB with pentoxifylline (PTX) or STAT-3 with Stattic (STT) is known to increase the sensitivity of tumor cells to chemotherapy in both in vitro and in vivo models. We investigated whether simultaneous blockade with PTX and STT increases the efficacy of the DTX treatment in inducing apoptosis in metastatic castration-resistant PCa DU-145 cells. Our results showed that the combination of PTX + STT led to higher levels of apoptosis, regardless of whether or not DTX was present in the treatment. Determining caspases and ΔΨm indicates that the intrinsic caspase pathway of apoptosis is principally favored. In addition, this combination inhibited proliferation and colony formation and arrested the cell cycle in the G1 phase. These results indicate that the combination of the PTX + STAT-3 inhibitor could potentiate DTX effectively, opening the possibility of effective treatments in PCa.
The emerging role of Buddhism in clinical psychology: Toward effective integration.

E. Shonin,W. Gordon,M. Griffiths

DOI: https://doi.org/10.1037/A0035859

2014-05-01

Abstract:Research into the clinical utility of Buddhist-derived interventions (BDIs) has increased greatly over the last decade. While clinical interest has predominantly focused on mindfulness meditation, there has also been an increase in the scientific investigation of interventions that integrate other Buddhist principles such as compassion, loving kindness, and ‘non-self’. However, due to the rapidity at which Buddhism has been assimilated into the mental health setting, issues relating to the misapplication of Buddhist terms and practices have sometimes arisen. Indeed, hitherto, there has been no unified system for the effective clinical operationalization of Buddhist principles. Therefore, this paper aims to establish robust foundations for the ongoing clinical implementation of Buddhist principles by providing: (i) succinct and accurate interpretations of Buddhist terms and principles that have become embedded into the clinical practice literature, (ii) an overview of current directions in the clinical operationalization of BDIs, and (iii) an assessment of BDI clinical integration issues. It is concluded that BDIs may be effective treatments for a variety of psychopathologies including mood-spectrum disorders, substance-use disorders, and schizophrenia. However, further research and clinical evaluation is required to strengthen the evidence-base for existent interventions and for establishing new treatment applications. More importantly, there is a need for greater dialogue between Buddhist teachers and mental health clinicians and researchers in order to safeguard the ethical values, efficacy, and credibility of BDIs.
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90 Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors

Anusha Muralidhar,Reinier Hernandez,Zachary S Morris,Hansel Comas Rojas,Malick Bio Idrissou,Jamey P Weichert,Douglas G McNeel

DOI: https://doi.org/10.1136/jitc-2023-008760

IF: 12.469

2024-04-01

Journal for ImmunoTherapy of Cancer

Abstract:Rationale Androgen deprivation therapy (ADT) is pivotal in treating recurrent prostate cancer and is often combined with external beam radiation therapy (EBRT) for localized disease. However, for metastatic castration-resistant prostate cancer, EBRT is typically only used in the palliative setting, because of the inability to radiate all sites of disease. Systemic radiation treatments that preferentially irradiate cancer cells, known as radiopharmaceutical therapy or targeted radionuclide therapy (TRT), have demonstrable benefits for treating metastatic prostate cancer. Here, we explored the use of a novel TRT, 90 Y-NM600, specifically in combination with ADT, in murine prostate tumor models. Methods 6-week-old male FVB mice were implanted subcutaneously with Myc-CaP tumor cells and given a single intravenous injection of 90 Y-NM600, in combination with ADT (degarelix). The combination and sequence of administration were evaluated for effect on tumor growth and infiltrating immune populations were analyzed by flow cytometry. Sera were assessed to determine treatment effects on cytokine profiles. Results ADT delivered prior to TRT (ADT→TRT) resulted in significantly greater antitumor response and overall survival than if delivered after TRT (TRT→ADT). Studies conducted in immunodeficient NRG mice failed to show a difference in treatment sequence, suggesting an immunological mechanism. Myeloid-derived suppressor cells (MDSCs) significantly accumulated in tumors following TRT→ADT treatment and retained immune suppressive function. However, CD4+ and CD8+ T cells with an activated and memory phenotype were more prevalent in the ADT→TRT group. Depletion of Gr1+MDSCs led to greater antitumor response following either treatment sequence. Chemotaxis assays suggested that tumor cells secreted chemokines that recruited MDSCs, notably CXCL1 and CXCL2. The use of a selective CXCR2 antagonist, reparixin, further improved antitumor responses and overall survival when used in tumor-bearing mice treated with TRT→ADT. Conclusion The combination of ADT and TRT improved antitumor responses in murine models of prostate cancer, however, this was dependent on the order of administration. This was found to be associated with one treatment sequence leading to an increase in infiltrating MDSCs. Combining treatment with a CXCR2 antagonist improved the antitumor effect of this combination, suggesting a possible approach for treating advanced human prostate cancer.

oncology,immunology
Tumor-Associated Macrophage Promotes the Survival of Cancer Cells upon Docetaxel Chemotherapy via the CSF1/CSF1R–CXCL12/CXCR4 Axis in Castration-Resistant Prostate Cancer

Wei Guan,Fan Li,Zhenyu Zhao,Zongbiao Zhang,Junhui Hu,Yan Zhang

DOI: https://doi.org/10.3390/genes12050773

IF: 4.141

2021-05-19

Genes

Abstract:Castration-resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that can progress rapidly even in patients treated with castration. Previously, we found that tumor-associated macrophages (TAM) can be recruited by CSF-1 secreted by docetaxel-treated prostate cancer cells and promote the survival of cancer cells in response to chemotherapy. The inhibition of CSF-1R can impede this effect and significantly prolong survival in xenograft mice. However, the actual mechanism of how TAM improves cancer cell survival still remains elusive and controversial. Here, for the first time, we found that the enhanced survival of cancer cells achieved by TAM was mainly mediated by CXCR4 activation from the increased secretion of CXCL12 from CSF-1 activated TAM. This finding helps to clarify the mechanism of chemoresistance for second-line chemotherapy using docetaxel, facilitating the development of novel drugs to overcome immune tolerance in castration-resistant prostate cancer.

genetics & heredity
Efficacy and Toxicity of Molecular Targeted Therapies in Combination with Docetaxel for Metastatic Castration-Resistant Prostate Cancer: a Meta-Analysis of Phase III Randomized Controlled Trials

Wei-Xiang Qi,Shen Fu,Qing Zhang,Xiao-Mao Guo

DOI: https://doi.org/10.1179/1973947814y.0000000230

2014-01-01

Journal of Chemotherapy

Abstract:Purpose: For patients with metastatic castration-resistant prostate cancer (CRPC), the efficacy and safety of molecular targeted agents (MTAs) in combination with docetaxel are still unclear. We conducted this meta-analysis to assess the efficacy and toxicity of the addition of MTAs to docetaxel-based chemotherapy for the treatment of metastatic CRPC.Methods: Databases from PubMed, Web of Science, and abstracts presented at American Society of Clinical Oncology meeting up to 31 June 2014 were searched to identify relevant studies. Eligible studies included prospective phase III randomized controlled trials (RCTs) evaluating docetaxel with or without MTAs in patients with metastatic CRPC. The primary aim was to assess overall survival (OS). Secondary aims were to assess progression-free survival (PFS); overall response rates (ORRs), and grade 3-5 toxicities. Statistical analyses were conducted by using either random effects or fixed-effect models according to the heterogeneity of included studies.Results: A total of 5886 patients from five phase III RCTs were identified. No statistically significant difference in OS [hazard ratio (HR): 0.98, 95% confidence interval (CI): 0.91-1.04, P=0.44], ORR [relative risk (RR): 1.32, 95% CI: 0.94-1.84, P=0.11], and PSA response rate (RR: 1.22, 95% CI: 0.86-1.74, P=0.27) was found between the two groups. The addition of MTAs to docetaxel significantly improved PFS (HR: 0.92, 95% CI: 0.86-0.98, P=0.011). However, the benefits in PFS was accompanied by increasing the risk of developing grade 3-4 (RR: 1.19, 95% CI: 0.99-1.42, P=0.062) and fatal (RR: 1.30, 95% CI: 1.01-1.66, P=0.039) adverse events.Conclusions: The findings of this study suggest that the palliation of CRPC with MTAs and docetaxel does not provide a significant survival benefit and is associated with increased severe toxicities.
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis

M Katie Conley-LaComb,Louie Semaan,Rajareddy Singareddy,Yanfeng Li,Elisabeth I Heath,Seongho Kim,Michael L Cher,Sreenivasa R Chinni

DOI: https://doi.org/10.1186/s12943-016-0552-0

2016-11-03

Abstract:Background: The CXCL12/CXCR4 axis transactivates HER2 and promotes intraosseous tumor growth. To further explore the transactivation of HER2 by CXCL12, we investigated the role of small GTP protein Gαi2 in Src and HER2 phosphorylation in lipid raft membrane microdomains and the significance of CXCR4 in prostate cancer bone tumor growth. Methods: We used a variety of methods such as lipid raft isolation, invasion assays, an in vivo model of intratibial tumor growth, bone histomorphometry, and immunohistochemistry to determine the role of CXCR4 signaling in lipid raft membrane microdomains and effects of targeting of CXCR4 for bone tumor growth. Results: We determined that (a) CXCL12/CXCR4 transactivation of EGFR and HER2 is confined to lipid raft membrane microdomains, (b) CXCL12 activation of HER2 and Src is mediated by small GTP proteins in lipid rafts, (c) inhibition of the CXCL12/CXCR4 axis through plerixafor abrogates the initial establishment of tumor growth without affecting the growth of established bone tumors, and (d) inhibition of EGFR signaling through gefitinib leads to inhibition of established bone tumor growth. Conclusions: These data suggest that lipid raft membrane microdomains are key sites for CXCL12/CXCR4 transactivation of HER2 via small GTP binding protein Gαi2 and Src kinase. The initial establishment of prostate cancer is supported by the endosteal niche, and blocking the CXCL12/CXCR4 axis of this niche along with its downstream signaling severely compromises initial establishment of tumors in the bone microenvironment, whereas expanding bone tumors are sensitive only to the members of growth factor receptor inhibition.
SREBP1 Sirna Enhance the Docetaxel Effect Based on a Bone-Cancer Dual-Targeting Biomimetic Nanosystem Against Bone Metastatic Castration-Resistant Prostate Cancer

Jiyuan Chen,Zhenjie Wu,Weihong Ding,Chengwu Xiao,Yu Zhang,Shen Gao,Yuan Gao,Weimin Cai

DOI: https://doi.org/10.7150/thno.40489

IF: 11.6

2020-01-01

Theranostics

Abstract:Until recently, there have been limited options for patients with bone metastatic castration-resistant prostate cancer (BmCRPC) following the failure of or development of resistance to docetaxel (DTX), which is one of the frontline treatments. Sterol regulatory element-binding protein 1 (SREBP1) is reported to regulate abnormal lipid metabolism and to promote the progression and metastasis of prostate cancer (PCa). The siRNA interferes SREBP1 may provide an efficient treatment when combined with DTX. Methods: In this study, lipoic acid (LA) and cross-linked peptide-lipoic acid micelles were cross-linked (LC) for DTX and siSREBP1 delivery (LC/D/siR). Then, cell membrane of PCa cells (Pm) and bone marrow mesenchymal stem cells (Bm) were fused for cloaking LC/D/siR (PB@LC/D/siR). Finally, the synthesized PB@LC/D/siR was evaluated in vitro and in vivo. Results: PB@LC/D/siR is internalized in PCa cells by a mechanism of lysosome escape. Tumor targeting and bone homing studies are evaluated using bone metastatic CRPC (BmCRPC) models, both in vitro and in vivo. Moreover, the enhanced anti-proliferation, anti-migration and anti-invasion capacities of DTX- and siSREBP1- loaded PB@LC (PB@LC/D/siR) were observed in vitro. Furthermore, PB@LC/D/siR was able to suppress the growth of the tumor effectively with deep tumor penetration, high safety and good protection of the bone at the tumor site. Additionally, the mRNA levels and protein levels of SREBP1 and SCD1 were able to be significantly downregulated by PB@LC/D/siR. Conclusion: This study presented a bone-cancer dual-targeting biomimetic nanodelivery system for bone metastatic CRPC.
Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer

Depei Kong,Chen Ye,Chenxi Zhang,Xiaochen Sun,Fubo Wang,Rui Chen,Guangan Xiao,Shipeng He,Jianrong Xu,Xiwu Rao,Jianzhong Ai,Xu Gao,Hong Li,Li Su

DOI: https://doi.org/10.1186/s13046-023-02610-7

2023-02-09

Abstract:Background: Bone is the most common site of metastasis of prostate cancer (PCa). PCa invasion leads to a disruption of osteogenic-osteolytic balance and causes abnormal bone formation. The interaction between PCa and bone stromal cells, especially osteoblasts (OB), is considered essential for the disease progression. However, drugs that effectively block the cancer-bone interaction and regulate the osteogenic-osteolytic balance remain undiscovered. Methods: A reporter gene system was constructed to screen compounds that could inhibit PCa-induced OB activation from 631 compounds. Then, the pharmacological effects of a candidate drug, Procoxacin (Pro), on OBs, osteoclasts (OCs) and cancer-bone interaction were studied in cellular models. Intratibial inoculation, micro-CT and histological analysis were used to explore the effect of Pro on osteogenic and osteolytic metastatic lesions. Bioinformatic analysis and experiments including qPCR, western blotting and ELISA assay were used to identify the effector molecules of Pro in the cancer-bone microenvironment. Virtual screening, molecular docking, surface plasmon resonance assay and RNA knockdown were utilized to identify the drug target of Pro. Experiments including co-IP, western blotting and immunofluorescence were performed to reveal the role of Pro binding to its target. Intracardiac inoculation metastasis model and survival analysis were used to investigate the therapeutic effect of Pro on metastatic cancer. Results: Luciferase reporter gene consisted of Runx2 binding sequence, OSE2, and Alp promotor could sensitively reflect the intensity of PCa-OB interaction. Pro best matched the screening criteria among 631 compounds in drug screening. Further study demonstrated that Pro effectively inhibited the PCa-induced osteoblastic changes without killing OBs or PCa cells and directly killed OCs or suppressed osteoclastic functions at very low concentrations. Mechanism study revealed that Pro broke the feedback loop of TGF-β/C-Raf/MAPK pathway by sandwiching into 14-3-3ζ/C-Raf complex and prevented its disassociation. Pro treatment alleviated both osteogenic and osteolytic lesions in PCa-involved bones and reduced the number of metastases of PCa in vivo. Conclusions: In summary, our study provides a drug screening strategy based on the cancer-host microenvironment and demonstrates that Pro effectively inhibits both osteoblastic and osteoclastic lesions in PCa-involved bones, which makes it a promising therapeutic agent for PCa bone metastasis.
Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial

Tie Zhou,Shengfei Qin,Weidong Xu,Shouyan Tang,Guanghua Chen,Song Li,Jianguo Hou,Xu Gao,Guowei Shi,Zhongquan Sun,Jie Jin,Lijun Chen,Weibing Sun,Ben Liu,Jingen Wang,Qinggui Meng,Dongwen Wang,Zhiquan Hu,Dalin He,Yong Yang,Xishuang Song,Cheng Fu,Yinhuai Wang,Dingwei Ye,Wei Zhang

DOI: https://doi.org/10.1002/ijc.34512

2023-01-01

International Journal of Cancer

Abstract:We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing =grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).
Potent Antitumour of the Mtorc1/2 Dual Inhibitor AZD2014 in Docetaxel‐sensitive and Docetaxel‐resistant Castration‐resistant Prostate Cancer Cells

Senmao Li,Jindong Sheng,Zhenhua Liu,Yu Fan,Cuijian Zhang,Tianjing Lv,Shuai Hu,Jie Jin,Wei Yu,Yi Song

DOI: https://doi.org/10.1111/jcmm.16155

2021-01-01

Journal of Cellular and Molecular Medicine

Abstract:Recent studies indicate mammalian target of rapamycin (mTOR) may play an important role in PCa progression and drug resistance. Here, we investigated the effects of a novel mTORC1/C2 dual inhibitor, AZD2014, on naive and docetaxel (Doc)-pre-treated castration-resistant PCa (CRPC) cells and explored its therapeutic potential in CRPCs. In the current study, AZD2014 has a greater inhibitory effect against 4EBP1 and AKT phosphorylation than rapamycin in CRPC cells and prevented the feedback activation of AKT signalling. Importantly, AZD2014 suppressed CRPC cell growth in vitro by suppressing proliferation, apoptosis, cell cycle arrest at G1 phase and autophagy to a greater extent than rapamycin. Moreover, AZD2014 was more efficacious than rapamycin in inhibiting migration, invasion and EMT progression in Doc-sensitive and Doc-resistant CRPC cells. Overall, AZD2014 showed significant antitumour effects. Thereby, the current study highlights a reliable theoretical basis for the clinical application of AZD2014 in both Doc-sensitive and Doc-resistant CRPCs.

A new method for in vivo measurement of brain monoamine oxidase activity

39P CSF-1R Inhibitor (C019199) Enhances Antitumor Effect in Combination with Anti-Pd-1 Therapy on Murine Breast Cancer Models

Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Generating Broadcast Programs that Support Range Queries

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models

[Clinical Efficacy of Docetaxel Combined with Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer].

Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models

Improvement of Docetaxel Efficacy through Simultaneous Blockade of Transcription Factors NF-κB and STAT-3 Using Pentoxifylline and Stattic in Prostate Cancer Cells

The emerging role of Buddhism in clinical psychology: Toward effective integration.

Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90 Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors

Tumor-Associated Macrophage Promotes the Survival of Cancer Cells upon Docetaxel Chemotherapy via the CSF1/CSF1R–CXCL12/CXCR4 Axis in Castration-Resistant Prostate Cancer

Efficacy and Toxicity of Molecular Targeted Therapies in Combination with Docetaxel for Metastatic Castration-Resistant Prostate Cancer: a Meta-Analysis of Phase III Randomized Controlled Trials

Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis

SREBP1 Sirna Enhance the Docetaxel Effect Based on a Bone-Cancer Dual-Targeting Biomimetic Nanosystem Against Bone Metastatic Castration-Resistant Prostate Cancer

Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer

Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial

Potent Antitumour of the Mtorc1/2 Dual Inhibitor AZD2014 in Docetaxel‐sensitive and Docetaxel‐resistant Castration‐resistant Prostate Cancer Cells